AGL and urinary bladder cancer: Our findings strongly point to the importance of the HAS2-HA-CD44/RHAMM pathway for rapid growth of bladder cancer cells with loss of AGL and provides rational for targeting this pathway at various steps for “personalized” treatment of bladder cancer patients based of their AGL expression status.